• Home
  • Search Results
  • Monoclonal antibodies selective for α-synuclein oligomers/protofibrils recognize brain pathology in Lewy body disorders and α-synuclein transgenic mice with the disease-causing A30P mutation.

Monoclonal antibodies selective for α-synuclein oligomers/protofibrils recognize brain pathology in Lewy body disorders and α-synuclein transgenic mice with the disease-causing A30P mutation.

Journal of neurochemistry (2013-02-01)
Therese Fagerqvist, Veronica Lindström, Eva Nordström, Anna Lord, Stina M E Tucker, Xingjian Su, Charlotte Sahlin, Alex Kasrayan, Jessica Andersson, Hedvig Welander, Thomas Näsström, Mats Holmquist, Heinrich Schell, Philipp J Kahle, Hannu Kalimo, Christer Möller, Pär Gellerfors, Lars Lannfelt, Joakim Bergström, Martin Ingelsson
ABSTRACT

Inclusions of intraneuronal alpha-synuclein (α-synuclein) can be detected in brains of patients with Parkinson's disease and dementia with Lewy bodies. The aggregation of α-synuclein is a central feature of the disease pathogenesis. Among the different α-synuclein species, large oligomers/protofibrils have particular neurotoxic properties and should therefore be suitable as both therapeutic and diagnostic targets. Two monoclonal antibodies, mAb38F and mAb38E2, with high affinity and strong selectivity for large α-synuclein oligomers were generated. These antibodies, which do not bind amyloid-beta or tau, recognize Lewy body pathology in brains from patients with Parkinson's disease and dementia with Lewy bodies and detect pathology earlier in α-synuclein transgenic mice than linear epitope antibodies. An oligomer-selective sandwich ELISA, based on mAb38F, was set up to analyze brain extracts of the transgenic mice. The overall levels of α-synuclein oligomers/protofibrils were found to increase with age in these mice, although the levels displayed a large interindividual variation. Upon subcellular fractionation, higher levels of α-synuclein oligomers/protofibrils could be detected in the endoplasmic reticulum around the age when behavioral disturbances develop. In summary, our novel oligomer-selective α-synuclein antibodies recognize relevant pathology and should be important tools to further explore the pathogenic mechanisms in Lewy body disorders. Moreover, they could be potential candidates both for immunotherapy and as reagents in an assay to assess a potential disease biomarker.

MATERIALS
Product Number
Brand
Product Description

Supelco
Ammonium formate, eluent additive for LC-MS, LiChropur, ≥99.0%
Sigma-Aldrich
Formic acid, reagent grade, ≥95%
Sigma-Aldrich
Formic acid, puriss. p.a., ACS reagent, reag. Ph. Eur., ≥98%
Sigma-Aldrich
Formic acid, ACS reagent, ≥96%
Sigma-Aldrich
Ammonium formate, ≥99.995% trace metals basis
Sigma-Aldrich
Ammonium formate, reagent grade, 97%
Sigma-Aldrich
Formic acid, puriss., meets analytical specifications of DAC, FCC, 98.0-100%
Sigma-Aldrich
Ammonium formate solution, BioUltra, 10 M in H2O
Sigma-Aldrich
Ammonium formate, BioUltra, ≥99.0% (calc. based on dry substance, NT)
Sigma-Aldrich
Sodium formate, BioUltra, ≥99.0% (NT)
Sigma-Aldrich
Sodium formate, ACS reagent, ≥99.0%
Sigma-Aldrich
Formic acid, ACS reagent, ≥88%
Sigma-Aldrich
Potassium formate, ReagentPlus®, 99%
Sigma-Aldrich
Formic acid, ≥95%, FCC, FG
Sigma-Aldrich
Sodium formate, reagent grade, 97%
Sigma-Aldrich
Calcium formate, BioUltra, ≥99.0% (T)
Sigma-Aldrich
Formic acid solution, BioUltra, 1.0 M in H2O
Supelco
Calcium formate, Standard for quantitative NMR, TraceCERT®
Sigma-Aldrich
Cesium formate, 98%
Sigma-Aldrich
Sodium formate, 99.998% trace metals basis
Sigma-Aldrich
Sodium formate-13C, 99 atom % 13C
Sigma-Aldrich
Potassium formate, BioUltra, ≥99.0% (NT)
Sigma-Aldrich
Thallium(I) formate, 97%
Sigma-Aldrich
Basosiv M050, produced by BASF

Social Media

LinkedIn icon
Twitter icon
Facebook Icon
Instagram Icon

Merck

Research. Development. Production.

We are a leading supplier to the global Life Science industry with solutions and services for research, biotechnology development and production, and pharmaceutical drug therapy development and production.

© 2021 Merck KGaA, Darmstadt, Germany and/or its affiliates. All Rights Reserved.

Reproduction of any materials from the site is strictly forbidden without permission.